Rhythm BiosciencesFRA:0RY +0.96%31 3-Year ROIIC % is 325.36 as of Jun. 2025, which is at its 10-year median of 325.36. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Rhythm Biosciences ranks better than 90.2% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Rhythm Biosciences's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 325.36%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Rhythm Biosciences's 3-Year ROIIC % or its related term are showing as below:
FRA:0RY's 3-Year ROIIC % is ranked better than 90.2% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs FRA:0RY: 325.36
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Rhythm Biosciences 3-Year ROIIC % Related Terms
Rhythm Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0RY vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Rhythm Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's 3-Year ROIIC % falls into.
Rhythm Biosciences's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.892 (Jun. 2025) - -7.476 (Jun. 2022) )
/
( 1.302 (Jun. 2025) - 0.645 (Jun. 2022) )
=
3.584
/
0.657
=
545.51%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Rhythm Biosciences (FRA:0RY) has a 3-Year ROIIC % of 325.36 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Rhythm Biosciences and its competitors. This is near median its historical median of 325.36. According to the industry distribution chart, Rhythm Biosciences ranks #20 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 9.8%.
Is Rhythm Biosciences' 3-Year ROIIC % too high?
Rhythm Biosciences' current 3-Year ROIIC % of 325.36 is near median its 10-year median of 325.36. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.13. Rhythm Biosciences' value of 325.36 is 260188% above this industry median. Based on the distribution chart, Rhythm Biosciences ranks #20 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #20 out of 204 companies for 3-Year ROIIC %. This places Rhythm Biosciences in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.13. Rhythm Biosciences' value of 325.36 is 260188% above this benchmark. While the company's 10-year median is 325.36 vs. the industry median of 0.13, Rhythm Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current 3-Year ROIIC % of 325.36 is 260188% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current 3-Year ROIIC % is 325.36, which is near median its own 10-year median of 325.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current 3-Year ROIIC % of 325.36. The current 3-Year ROIIC % is 325.36, which is near median its 10-year median of 325.36 and 260188% above the Medical Diagnostics & Research industry median of 0.13. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current 3-Year ROIIC % is 325.36 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
